SCHEMBL6359259

SCHEMBL6359259

O=C1NC(=O)/C(=C/c2ccc(OCCn3cnc4ccccc4c3=O)cc2)S1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.57
HTT P42858 2/20 0.57
MEN1 O00255 1/20 0.57
ALDH1A1 P00352 1/20 0.57
GAA P10253 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
MAPK1 P28482 2/20 0.55
PTPN1 P18031 2/20 0.55
POLB P06746 1/20 0.55
PIM1 P11309 1/20 0.54
PIM2 Q9P1W9 1/20 0.54
LMNA P02545 2/20 0.53
HRH3 Q9Y5N1 1/20 0.53
RAB9A P51151 1/20 0.53
CISD1 Q9NZ45 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5935704 1.00 HPGD (0.57) HPGDHTTMEN1ALDH1A1GAA
SCHEMBL6854028 0.87 KMT2A (0.57) HPGDHTTMEN1ALDH1A1GAA
SCHEMBL5935606 0.82 HTT (0.69) HPGDHTTMEN1ALDH1A1GAA
SCHEMBL6359955 0.81 MAOA (0.56) HPGDMAOAMAOBPTPN1POLB
SCHEMBL5935575 0.81 MAOA (0.56) HPGDMAOAMAOBPTPN1POLB
SCHEMBL5935590 0.80 PIM1 (0.54) HPGDMAOAMAOBPTPN1POLB
SCHEMBL7009625 0.80 PIM1 (0.54) HPGDMAOAMAOBPTPN1POLB
SCHEMBL7462410 0.77 PIM1 (0.56) HPGDMAOAMAOBPTPN1POLB
SCHEMBL7013434 0.77 HPGD (0.62) HPGDALDH1A1MAOAMAOBPTPN1
SCHEMBL7457308 0.77 NPC1 (0.64) HPGDKMT2AMAOAMAOBPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032864-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S LABORATORIES LIMITED 2005-02-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032864-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B2 HPGD 489/4885HTT 597/4885MEN1 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.